<DOC>
	<DOC>NCT01420068</DOC>
	<brief_summary>52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1</brief_summary>
	<brief_title>52-104 Week Off-therapy Second Extension to Study CSPP100A2365</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Successful completion of study CSPP100A2365E1 Patients must meet inclusion criteria set forth for trials CSPP100A2365 and CSPP100A2365E1 Informed consent/ patient assent â€¢Patients who did not successfully complete studies CSPP100A2365 and CSPP100A2365E1</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>hypertension</keyword>
	<keyword>aliskiren</keyword>
</DOC>